
Proud to support @RManochakian in his candidacy for the #ASCO Nominating Committee! An outstanding colleague and a dedicated leader with a strong commitment to our oncology community. Wishing you every success, Rami! 👏
✓MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM

Proud to support @RManochakian in his candidacy for the #ASCO Nominating Committee! An outstanding colleague and a dedicated leader with a strong commitment to our oncology community. Wishing you every success, Rami! 👏

📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca. 📊 mINV-PFS: 22 mo | OS: 40 mo 🚀 Can IO, ADCs & bispecifics move to 1st line? 💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies! 🔗 authors.elsevier.com/a/1o6FL…

Report @JTOonline showing tarlatamab efficacy in pts with atypical carcinoid (n=5, RR 60%, DCR 100%, mPFS 8.8m) and large cell neuroendocrine carcinoma (LCNEC, n=7, RR 43%, DCR 88%, mPFS 5.1m). DLL3 IHC potential predictive marker here. jtocrr.org/article/S2666-364…

Latest update to @ASCO Living Guidelines from @Joshua_Reuss et al reaffirms first line lorlatinib for patients with advanced ALK+ NSCLC with use of alectinib, brigatinib, or ensartinib only when lorlatinib not suitable or available. ascopubs.org/doi/10.1200/JCO…

Negative phase III KEYNOTE-867 @JCO_ASCO. Pts with stage I-II NSCLC treated with SBRT with pembro vs placebo (n=448). No difference in EFS (31.2 vs 28.3m, HR 0.92). Poor partner, wrong setting, or both? Adjuvant IO approaches in general disappointing. ascopubs.org/doi/10.1200/JCO…

Patterns of progression in ADRIATIC (durvalumab consolidation post CRT for LS-SCLC) @JTOonline. Similar rates of intrathoracic progression but lower extrathoracic progression with durvalumab (20% vs 30%) including brain (6.8% vs 12.4%). jto.org/article/S1556-0864(2…

Speakers from Japan, Portugal, France, Italy, Germany, Greece, the Netherlands and the USA come to Lausanne on 13 November. Millie Das (@DasMillie11), Hidehito Horinouchi (@HHorinouchi), Telma Sequeira (@TelmaSequeiraMD), Christine Lovly (@christine_lovly), David Planchard (@dplanchard), Sandip Patel (@PatelOncology), Alessio Cortellini (@ACortelliniMD), Nikolaj Frost, Giannis Mountzios (@g_mountzios) and Anne-Marie Dingemans (@a_dingemans) speak at the International Lung Cancer Summit (ILCS) 2026, at CHUV and online, with Solange Peters (@peters_solange) and Alfredo Addeo (@Alfdoc2) in the chair. We look forward to a day of good discussion with you. Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC #SCLC

⭕ ¡Ya disponible el coloquio final de #LungCancerUpdates Highlights #ESMO2026! 🗣️ La Dra. @AnaCardea5 (H. U. Nuestra Señora de Candelaria), el Dr. Alejandro Olivares (H. Clínico Universitario de Salamanca) y el Dr. @ManuelDomine ( @Hospital_FJD ) analizan las principales novedades presentadas durante el congreso. 👉Los investigadores del GECP debaten sobre los avances en la práctica clínica. ➡️ ¡Descubre el coloquio completo y las principales conclusiones de #ESMO2026! doctaforum-appexternas.org/-…

📣 Registration for #ELCC27 is now open. Join a focused, multidisciplinary thoracic oncology community to discuss the latest research, exchange perspectives and connect with colleagues from across the field. 🔗 Register now: ow.ly/sglQ50ZZctT #esmomeetings

#ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50% ➡️ ow.ly/85ir5100p5H #InsightsbyESMO @Alfdoc2

#ESMO26: Phase III OptiTROP-Lung06 #ClinicalTrial reports a game-changing 51% reduction in the risk of progression or death with the #ADC sacituzumab tirumotecan added to pembrolizumab in advanced #NSCLC ➡️ ow.ly/QYUT5102qlv #InsightsbyESMO @g_mountzios

Early ctDNA clearance went with longer EFS in resectable NSCLC across 3 NeoCOAST-2 arms, Tina Cascone and colleagues report in Nature. Among the authors is our faculty member Patrick Forde (@FordePatrick). 🔬 Phase 2 NeoCOAST-2 platform trial, resectable stage IIA–IIIB NSCLC, 3 additions to chemotherapy plus durvalumab 📊 ctDNA clearance at cycle 3: 50.9%, 54.5% and 72.5% with oleclumab, monalizumab and Dato-DXd 📊 Clearance vs no clearance: pooled EFS HR 0.22 (P=0.0000443) 📊 Clearance plus pCR vs neither: EFS HR 0.10 ⚠️ Exploratory association; ctDNA clearance was observed, not randomised Read in our article how the Dato-DXd arm compared on pCR. lungsummit.org/articles/earl…

So much anger and sadness. This should never happen. My heart goes out to the victims and their families.

Panelists: - Prof. Myung-Ju Ahn, Samsung Medical Center and Sungkyunkwan University School of Medicine - Prof. Noemí Reguart, Hospital Clínic de Barcelona - Prof. Ziming Li, Shanghai Chest Hospital @MedicalSamsung @SamsungMedical_ @NReguart @hospitalclinic @UniBarcelona


🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ @drgandara 🔢3809O 🎯Serplulimab Numerically Longer OS vs Atezolizumab 🎯mOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6% ☑️NCT05468489 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC